von Willebrand factor binds to native collagen VI primarily via its A1 domain.
Collagen VI is abundant in the arterial subendothelium. To investigate its mechanism of interaction with von Willebrand factor (vWF), collagen VI was isolated from human placenta and from the extracellular matrix of the human lung fibroblast cell line MRC-5. Purified vWF bound to non-digested collagen VI with moderately high affinity (EC50 approximately 5 nM) and could be inhibited by the Hirudo medicinalis collagen inhibitor calin. The anti-(human vWF A1 domain) monoclonal antibody (AJvW-2), as well as aurin tricarboxylic acid (ATA), at concentrations that saturate the vWF A1 domain, also inhibited this binding. In contrast, the monoclonal anti-(human vWF A3 domain) antibody (82D6A3) inhibited vWF binding to collagens I, III and IV, but had no effect on vWF binding to collagen VI. Likewise, vWF binding to collagen VI was not inhibited by the recombinant vWF domain D4. Polyclonal anti-(collagen VI) antibodies, specifically neutralizing the binding of vWF to collagen VI, confirmed that in the intact endothelial cell extracellular matrix, collagen VI was accessible for interaction with vWF. This binding was only marginally affected by 82D6A3 but was dose-dependently inhibited by AJvW-2, ATA and the A1 domain analogue VCL (recombinant A1 domain of vWF), with IC50 values comparable to those found for the inhibition of vWF binding to isolated collagen VI. The weak interaction of isolated human platelets with collagen VI was mediated via the platelet collagen receptor (GPIa/IIa) and was competitively inhibited by vWF but not by VCL, suggesting that vWF and GPIa/IIa bind to neighbouring but distinct sites on collagen VI. We conclude that vWF binds to collagen VI primarily via its A1 domain, which distinguishes it from the vWF A3 domain-mediated binding to fibrillar collagens.
Hoylaerts
M F
MF
Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.
Yamamoto
H
H
Nuyts
K
K
Vreys
I
I
Deckmyn
H
H
Vermylen
J
J
D000911:Antibodies, Monoclonal; D001312:Aurintricarboxylic Acid / Q000494:pharmacology; D001665:Binding Sites; D001792:Blood Platelets / Q000502:physiology; D002460:Cell Line; D002850:Chromatography, Gel; D003094:Collagen / Q000737:chemistry* / Q000302:isolation & purification / Q000378:metabolism*; D005109:Extracellular Matrix; D005260:Female; D005347:Fibroblasts; D006801:Humans; D007447:Invertebrate Hormones / Q000494:pharmacology; D007700:Kinetics; D008168:Lung; D010920:Placenta; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011247:Pregnancy; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D012471:Salivary Proteins and Peptides / Q000494:pharmacology; D014841:von Willebrand Factor / Q000737:chemistry* / Q000302:isolation & purification / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D007447:Invertebrate Hormones; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D012471:Salivary Proteins and Peptides; D014841:von Willebrand Factor; C072490:calin; D001312:Aurintricarboxylic Acid; D003094:Collagen